LOXL2 and Hepatic fibrosis: Additionally, miR-27-3p has the potential to ameliorate liver fibrosis by reducing YAP expression, thereby inhibiting Lysyl oxidase-like 2 (LOXL2) and subsequently suppressing HSCs activation [27].